Bioequivalence and Bioavailability Forum

1. In R, there is no way to calculate Type III MS (still same right now?) when we developed bear, but Type I MS. SAS can calculate both. Only when you have a complete crossover study design (same subj. # for ref. and test), Type I MS will be equal to Type III MS, as you can see from your bear output file. That's what we do with bear.
   
2. We validated ANOVA results obtained from bear with SAS whiles ago. And we got the same results using the dataset of a complete crossover study design.
   
3. I don't know how WNL calculates Type I/III MS. But I would strongly suggest that you probably should use SAS to confirm your validations.
   

❝ As you can see according to bear there is a sequence effect for AUCo-t while in WinNonlin it's not. This same situation happen with AUC0-Inf.

❝ However, the results for NCA, period, drug, seq(subj) effect, Confidence Intervals are exactly the same in both programs. So, why only the sequence effect is different?